ARCHIVES

NCI Planning To Switch Drug Development Emphasis From Compound To Human Cancer Oriented Strategy

This article is from The Cancer Letter archive.

Vol. 10 No. 41 | October 26, 1984

Download PDF Visit The Full Archive

Related Articles

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

December 10, 2004

Ralph Steinman Wins Nobel Prize Three Days After His Death

October 14, 2011

Risk Assessment Key In Long-Term Treatment

August 29, 2008

Cancer Programs Close Amid Gridlock

October 4, 2013

New Edition Of Book On Cancer Rates, Risks, Available

February 28, 1997

In Brief: NCI Awards 4 Contracts For Enrichment Program; Dana-Farber Names Breast Center Leadership

July 10, 1992